AstraZeneca India appoints Ram Mudaliar as India lead of their CDI division
Ram’s appointment follows the launch of the CDI India division in October 2021.
Ram’s appointment follows the launch of the CDI India division in October 2021.
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
They will commercialize molnupiravir in the international markets
This is the company’s first partnership arrangement in China
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
He holds nine US patents and has published in multiple peer-reviewed journals and conferences
It provides Covid-19 detection and Omicron surveillance in less than two hours
New capabilities on Philips Image Guided therapy mobile C-arm system – Zenition – and collaboration with Cydar offer the latest advances in endovascular treatment
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
Subscribe To Our Newsletter & Stay Updated